JSPR

MKT CAP:$14M

Jasper Therapeutics, Inc.

Market Cap

$14M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$0.91-$0.93 (-50.81%)

Apr 23, 2026

Company Details

Jasper Therapeutics, Inc., a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. It focuses on the development and commercialization of conditioning agents and st...

CEO

Jeetinder Singh Mahal

IPO Date

Jan 10, 2020

Website

jaspertherapeutics.com

Key Metrics TTM

Revenue

$0

— YoY

Net Income

-$91M

EPS (Diluted)

-$5.90

Free Cash Flow

-$77M

Revenue / Share

$0.00

Gross Margin

—

Operating Margin

—

Net Margin

—

FCF Margin

—

P/S

—

P/E

—

Earnings Reports

Q4 2025

May 11, 2026

PENDING

FY 2025

Mar 30, 2026

$0EPS -$3.95

Q3 2025

Nov 10, 2025

$0EPS -$1.13

Q2 2025

Aug 13, 2025

$0EPS -$1.74

Q1 2025

May 12, 2025

$0EPS -$1.41

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q4 21	$0	$0	-$12M
Q1 22	$0	$0	-$13M
Q2 22	$0	$0	-$12M
Q3 22	$0	$0	-$13M
Q4 22	$0	$0	-$14M
Q1 23	$0	$0	-$14M
Q2 23	$0	$0	-$18M
Q3 23	$0	$0	-$19M
Q4 23	$0	$0	-$18M
Q1 24	$0	-$288.0K	-$15M
Q2 24	$0	$0	-$16M
Q3 24	$0	$0	-$20M
Q4 24	$0	$0	-$25M
Q1 25	$0	$0	-$22M
Q2 25	$0	$0	-$27M
Q3 25	$0	$0	-$19M

Operating Cash Flow

Quarter	Operating CF	Free CF
Q4 21	-$15M	-$15M
Q1 22	-$14M	-$14M
Q2 22	-$9M	-$10M
Q3 22	-$10M	-$10M
Q4 22	-$13M	-$13M
Q1 23	-$10M	-$10M
Q2 23	-$13M	-$13M
Q3 23	-$12M	-$12M
Q4 23	-$16M	-$17M
Q1 24	-$16M	-$16M
Q2 24	-$12M	-$12M
Q3 24	-$14M	-$14M
Q4 24	-$21M	-$21M
Q1 25	-$23M	-$23M
Q2 25	-$15M	-$15M
Q3 25	-$17M	-$17M

Capital Expenditures

Quarter	CapEx
Q4 21	$711.0K
Q1 22	$29.0K
Q2 22	$243.0K
Q3 22	$222.0K
Q4 22	$82.0K
Q1 23	$26.0K
Q2 23	$11.0K
Q3 23	$0
Q4 23	$230.0K
Q1 24	$25.0K
Q2 24	$157.0K
Q3 24	$274.0K
Q4 24	$96.0K
Q1 25	$0
Q2 25	$7.0K
Q3 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q4 21	—	+102.8%
Q1 22	—	+104.3%
Q2 22	—	+42.1%
Q3 22	—	+26.1%
Q4 22	—	+13.8%
Q1 23	—	+9.1%
Q2 23	—	+49.0%
Q3 23	—	+52.4%
Q4 23	—	+28.9%
Q1 24	—	+8.1%
Q2 24	—	-10.3%
Q3 24	—	+2.7%
Q4 24	—	+42.7%
Q1 25	—	+44.7%
Q2 25	—	+69.3%
Q3 25	—	-3.6%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q4 21	$0	—
Q1 22	$0	—
Q2 22	$0	—
Q3 22	$0	—
Q4 22	$0	—
Q1 23	$1M	—
Q2 23	$0	—
Q3 23	$1M	—
Q4 23	$1M	—
Q1 24	$1M	—
Q2 24	$1M	—
Q3 24	$0	—
Q4 24	$2M	—
Q1 25	$2M	—
Q2 25	$2M	—
Q3 25	$1M	—

OpEx Breakdown

Quarter	R&D	G&A
Q4 21	$9M	$3M
Q1 22	$8M	$5M
Q2 22	$8M	$4M
Q3 22	$9M	$4M
Q4 22	$9M	$4M
Q1 23	$10M	$4M
Q2 23	$13M	$5M
Q3 23	$15M	$5M
Q4 23	$14M	$4M
Q1 24	$10M	$5M
Q2 24	$11M	$5M
Q3 24	$14M	$5M
Q4 24	$20M	$6M
Q1 25	$16M	$6M
Q2 25	$21M	$6M
Q3 25	$14M	$5M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$70M	$0	$70M
Q2 22	$61M	$0	$61M
Q3 22	$51M	$0	$51M
Q4 22	$38M	$0	$38M
Q1 23	$129M	$0	$129M
Q2 23	$116M	$0	$116M
Q3 23	$104M	$0	$104M
Q4 23	$87M	$0	$87M
Q1 24	$118M	$0	$118M
Q2 24	$107M	$0	$107M
Q3 24	$93M	$0	$93M
Q4 24	$72M	$0	$72M
Q1 25	$49M	$0	$49M
Q2 25	$40M	$0	$40M
Q3 25	$51M	$0	$51M
Q4 25	$29M	$0	$29M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q4 21	4M	+634.8%	+1881.0%
Q1 22	4M	-0.5%	+1733.0%
Q2 22	4M	+0.2%	+1629.2%
Q3 22	4M	+0.5%	+636.3%
Q4 22	4M	+0.2%	+0.4%
Q1 23	9M	+139.8%	+142.0%
Q2 23	11M	+24.3%	+200.1%
Q3 23	11M	+0.5%	+200.1%
Q4 23	11M	+0.7%	+201.3%
Q1 24	13M	+20.7%	+51.7%
Q2 24	15M	+12.4%	+37.2%
Q3 24	15M	+0.1%	+36.7%
Q4 24	15M	+0.1%	+35.9%
Q1 25	15M	+0.1%	+12.7%
Q2 25	15M	+2.1%	+2.3%
Q3 25	17M	+8.5%	+10.9%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q4 21	$0	25
Q1 22	$0	25
Q2 22	$0	25
Q3 22	$0	25
Q4 22	$0	35
Q1 23	$0	35
Q2 23	$0	35
Q3 23	$0	35
Q4 23	$0	45
Q1 24	$0	45
Q2 24	$0	45
Q3 24	$0	45
Q4 24	$0	64
Q1 25	$0	64
Q2 25	$0	64
Q3 25	$0	64

Revenue / Employee